Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active- and Placebo-Controlled, Single-Dummy, 4-Way Crossover Study to Determine the Abuse Potential of Pitolisant Compared to Phentermine and Placebo, in Healthy, Non-Dependent Recreational Stimulant Users

Next Previous
Trial Profile

A Randomized, Double-Blind, Active- and Placebo-Controlled, Single-Dummy, 4-Way Crossover Study to Determine the Abuse Potential of Pitolisant Compared to Phentermine and Placebo, in Healthy, Non-Dependent Recreational Stimulant Users

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitolisant (Primary) ; Phentermine
  • Indications Hypersomnia; Narcolepsy; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Bioprojet

Most Recent Events

  • 20 Nov 2019 According to a Harmony Biosciences media release, results from this study were presented World Sleep 2019 meeting.
  • 20 Nov 2019 According to a Harmony Biosciences media release, results from this study were published in the Sleep.
  • 16 Sep 2019 According to a Harmony Biosciences media release, data from this trial will be presented at the World Sleep 2019 meeting in Vancouver, Canada from September 20-25, 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top